Ex Vivo Cell & Gene Therapies
Providing the engineering expertise to
optimize therapies for patients.
// Therapeutic Design
& Approaches
Engineering Cells for Novel Therapeutics
Ex vivo cell and gene therapies are living medicines in which immune cells and genetic material are engineered outside of the body and then reintroduced to patients. This engineering is designed to improve immune cells’ ability to fight disease.
ElevateBio modifies the genetic material through its proprietary gene editing technologies and engineering expertise to optimize therapies and directly target the source of disease.
Enabled By Our End-to-End Capabilities and Platform Technologies
Our platform technology approach combined with our industry-leading expertise to design, manufacture, and develop advanced next-generation therapies enables us and our partners to bring novel treatments to patients.
Ex Vivo Cell & Gene Therapies
Autologous Cell TherapyAutologous cell therapy is a form of personalized medicine that uses a patient’s own genetically modified immune cells to treat disease. In autologous therapies, cells are removed from a patient, engineered to elicit the desired therapeutic effect, and reintroduced to the patient. To create autologous therapies, like chimeric antigen receptor (CAR) T and T cell receptor (TCR) cell therapies, ElevateBio combines target selection, cell and vector engineering and gene editing to modify cells and optimize their performance. |  |
Allogeneic Cell TherapyAllogeneic cell therapy is an ‘off-the-shelf’ form of immunotherapy designed to be readily accessible for patients. Cells are derived from healthy donors or cell lines and engineered to be available for treatments on demand. Allogeneic therapies can be highly scalable with increased manufacturing efficiency relative to autologous approaches. ElevateBio leverages its deep gene editing and cell and vector engineering expertise to optimize cells for allogeneic cell therapies. |  |
iPSC-Derived Regenerative MedicinesInduced pluripotent stem cell (iPSC)-derived regenerative medicines offer tremendous potential to treat disease directly at the source. iPSCs can differentiate into any cell or tissue type and be engineered for a variety of therapeutic applications, including cancer or tissue regeneration. ElevateBio’s iPSC platform offers unique approaches to cell line generation and differentiation, which can improve manufacturing efficiency and accelerate the development of life-transforming therapies. |  |
Lentiviral Vector Cell & Gene TherapiesLentiviral vectors are a method to deliver a gene as a therapy for patients. Engineered outside of the body, lentiviral vectors can be used to express the gene of interest in autologous, allogeneic, and iPSC-derived cell therapies. Through our proprietary LentiPeak™ platform, ElevateBio has created a robust and scalable process for the development of lentiviral vectors, enabling efficient transition from preclinical through clinical development and commercialization. |  |
Powering Cell and Gene Therapies with Our Technology Platforms
With proprietary gene editing, iPSCs, and cell, protein, and vector engineering technologies and the ability to combine them, we can power the entire cell and gene therapy industry.
End-to-End Capabilities
We help our partners scale new heights in cell and gene therapies by providing a full spectrum of viral vector and cell therapy capabilities to bring concepts to commercialization.
Partner with ElevateBio®
Wherever you are in your product lifecycle, we can strengthen and accelerate the development of your transformative therapies with our enabling technologies unmatched manufacturing capabilities.
// Work with us
